After intervention with a GLP-1 receptor agonist, CRC cells can block the cell cycle, inhibit cell proliferation, migration and invasion, promote apoptosis, and reduce the expression of PI3K/Akt/mTOR pathway protein. Here, MTOR is linked to colorectal carcinoma.